drugset / Trial / NCT06008249
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
Phase 3
Terminated
88 enrolled
TRICALS Foundation
Alan Davidson Foundation · collabFightMND · collabLuzon Foundation · collabMNDA · collabMy name'5 Doddie Foundation · collabResearch Foundation Flanders · collabStichting ALS Nederland · collabThierry Latran Foundation · collabUlla-Carin Lindquist Foundation · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this phase III, placebo-controlled platform study is to investigate the efficacy of drugs for patients with ALS (Amyotrophic lateral sclerosis).
Timeline
- Start
- 2021-08-09
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
Outcome
Outcome not reported
Stopped: “The planned interim analysis showed no survival benefit of taking the drug when compared with placebo.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lithium Carbonate | Unknown | 400 mg | — |